Jubilant FoodWorks Limited (BOM:533155)
India · Delayed Price · Currency is INR 641.40
-7.80 (-1.20%)
At close: Aug 5, 2025
Marinus Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 81,417 | 56,551 | 51,582 | 43,961 | 33,119 | Upgrade | |
Revenue Growth (YoY) | 43.97% | 9.63% | 17.34% | 32.74% | -15.67% | Upgrade |
Cost of Revenue | 38,569 | 25,606 | 22,911 | 18,685 | 15,618 | Upgrade |
Gross Profit | 42,848 | 30,944 | 28,671 | 25,277 | 17,501 | Upgrade |
Selling, General & Admin | 5,886 | 3,603 | 768.06 | 468.48 | 120.32 | Upgrade |
Other Operating Expenses | 21,097 | 15,748 | 16,283 | 13,641 | 10,264 | Upgrade |
Operating Expenses | 35,048 | 25,331 | 21,909 | 18,040 | 13,932 | Upgrade |
Operating Income | 7,800 | 5,614 | 6,762 | 7,237 | 3,570 | Upgrade |
Interest Expense | -5,209 | -2,878 | -2,012 | -1,761 | -1,627 | Upgrade |
Interest & Investment Income | 475.8 | 218.49 | 267.29 | 294.5 | 414.25 | Upgrade |
Earnings From Equity Investments | -45.51 | 159.09 | -261.22 | -104.03 | - | Upgrade |
Other Non Operating Income (Expenses) | 84.14 | 117.98 | 32.92 | 22.29 | 29.85 | Upgrade |
EBT Excluding Unusual Items | 3,106 | 3,232 | 4,788 | 5,689 | 2,387 | Upgrade |
Gain (Loss) on Sale of Investments | 59.11 | 55.78 | 73.56 | 56.04 | 53.29 | Upgrade |
Gain (Loss) on Sale of Assets | -142.78 | -148.7 | -105.05 | -79.8 | -88.53 | Upgrade |
Asset Writedown | - | - | - | - | -206.71 | Upgrade |
Other Unusual Items | 72.18 | 1,718 | 130.35 | -32.54 | 916.99 | Upgrade |
Pretax Income | 3,094 | 4,857 | 4,887 | 5,633 | 3,062 | Upgrade |
Income Tax Expense | 773.71 | 849.64 | 1,357 | 1,452 | 756.52 | Upgrade |
Earnings From Continuing Operations | 2,321 | 4,008 | 3,530 | 4,181 | 2,305 | Upgrade |
Earnings From Discontinued Operations | -149.53 | -6.79 | - | - | - | Upgrade |
Net Income to Company | 2,171 | 4,001 | 3,530 | 4,181 | 2,305 | Upgrade |
Minority Interest in Earnings | -63.58 | -7.29 | 1.67 | 23.03 | 11.45 | Upgrade |
Net Income | 2,108 | 3,993 | 3,532 | 4,204 | 2,317 | Upgrade |
Net Income to Common | 2,108 | 3,993 | 3,532 | 4,204 | 2,317 | Upgrade |
Net Income Growth | -47.22% | 13.06% | -15.98% | 81.46% | -17.26% | Upgrade |
Shares Outstanding (Basic) | 660 | 660 | 660 | 660 | 660 | Upgrade |
Shares Outstanding (Diluted) | 660 | 660 | 660 | 660 | 660 | Upgrade |
EPS (Basic) | 3.19 | 6.05 | 5.35 | 6.37 | 3.51 | Upgrade |
EPS (Diluted) | 3.18 | 6.05 | 5.35 | 6.37 | 3.51 | Upgrade |
EPS Growth | -47.38% | 13.08% | -16.01% | 81.48% | -17.28% | Upgrade |
Free Cash Flow | 8,051 | 1,679 | 2,327 | 5,387 | 5,320 | Upgrade |
Free Cash Flow Per Share | 12.20 | 2.54 | 3.53 | 8.16 | 8.06 | Upgrade |
Dividend Per Share | 1.200 | 1.200 | 1.200 | 1.200 | 1.200 | Upgrade |
Gross Margin | 52.63% | 54.72% | 55.58% | 57.50% | 52.84% | Upgrade |
Operating Margin | 9.58% | 9.93% | 13.11% | 16.46% | 10.78% | Upgrade |
Profit Margin | 2.59% | 7.06% | 6.85% | 9.56% | 7.00% | Upgrade |
Free Cash Flow Margin | 9.89% | 2.97% | 4.51% | 12.26% | 16.06% | Upgrade |
EBITDA | 11,559 | 8,411 | 9,045 | 8,998 | 5,206 | Upgrade |
EBITDA Margin | 14.20% | 14.87% | 17.54% | 20.47% | 15.72% | Upgrade |
D&A For EBITDA | 3,759 | 2,797 | 2,284 | 1,761 | 1,636 | Upgrade |
EBIT | 7,800 | 5,614 | 6,762 | 7,237 | 3,570 | Upgrade |
EBIT Margin | 9.58% | 9.93% | 13.11% | 16.46% | 10.78% | Upgrade |
Effective Tax Rate | 25.00% | 17.49% | 27.77% | 25.77% | 24.71% | Upgrade |
Revenue as Reported | 82,171 | 56,960 | 52,087 | 44,375 | 33,849 | Upgrade |
Advertising Expenses | 4,619 | 2,530 | 2,052 | 3,093 | 2,789 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.